Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | CLK1 | P49759 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3548683 | 0.92 | NPC1 (0.39) | CYP1A2PIK3CAALDH1A1KMT2AGAA | |
| SCHEMBL23645428 | 0.91 | RAB9A (0.41) | CYP1A2PIK3CAALDH1A1KMT2AGAA | |
| SCHEMBL13118705 | 0.85 | CYP1A2 (0.42) | CYP1A2ALDH1A1KMT2AGAANPC1 | |
| SCHEMBL22275584 | 0.84 | ALDH1A1 (0.40) | CYP1A2ALDH1A1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL23645356 | 0.82 | FAAH (0.39) | CYP1A2PIK3CAJMJD6ALDH1A1KMT2A | |
| SCHEMBL3551607 | 0.79 | PIK3CA (0.44) | CYP1A2PIK3CAALDH1A1KMT2AGAA | |
| SCHEMBL19299941 | 0.79 | KMT2A (0.41) | CYP1A2PIK3CAJMJD6ALDH1A1KMT2A | |
| SCHEMBL19284267 | 0.78 | KMT2A (0.40) | CYP1A2ALDH1A1KMT2AGAAKDM4E | |
| SCHEMBL19299890 | 0.78 | KMT2A (0.40) | CYP1A2ALDH1A1KMT2AGAAKDM4E | |
| SCHEMBL19284286 | 0.78 | KMT2A (0.38) | CYP1A2ALDH1A1KMT2AGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120166987-A | Phthalazine derivatives as pyruvate kinase modulators | 西特瑞治疗有限公司 | 2025-06-17 | — | — | CN | disclosed |
| CN-119954831-A | Pyrimidopyrazoles, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-115873000-B | Isoquinolinones and quinazolinones compounds, and composition and application thereof | 中山医诺维申新药研发有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-118317951-A | Phthalazine derivatives as pyruvate kinase modulators | 西特瑞治疗有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20230270751-A1 | BENZODIAZEPINE DERIVATIVES USEFUL IN TREATING A RESPIRATORY SYNCYTIAL VIRUS INFECTION | PFIZER INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230270751-A1 | BENZODIAZEPINE DERIVATIVES USEFUL IN TREATING A RESPIRATORY SYNCYTIAL VIRUS INFECTION | PFIZER INC. | 2023-08-31 | — | — | US | disclosed |
| WO-2023079294-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | SITRYX THERAPEUTICS LIMITED (GB) | 2023-05-11 | — | — | WO | disclosed |
| CN-116075516-A | Benzodiazepine derivatives useful for the treatment of respiratory syncytial virus infection | 辉瑞大药厂 | 2023-05-05 | — | — | CN | disclosed |
| CN-115873000-A | Isoquinolone and quinazolinone compounds, and composition and application thereof | 中山医诺维申新药研发有限公司 | 2023-03-31 | — | — | CN | disclosed |
| CN-113429410-B | Polyheterocyclic substituted pyrimidine or pyridylamine derivatives, compositions and medical uses thereof | 上海海雁医药科技有限公司 | 2022-10-04 | — | — | CN | disclosed |
| WO-2022008911-A1 | BENZODIAZEPINE DERIVATIVES USEFUL IN TREATING A RESPIRATORY SYNCYTIAL VIRUS INFECTION | ReViral Limited (GB) | 2022-01-13 | — | — | WO | disclosed |
| CN-113429410-A | Polyheterocyclic substituted pyrimidine or pyridylamine derivatives, compositions and medical uses thereof | 上海海雁医药科技有限公司 | 2021-09-24 | — | — | CN | disclosed |
| US-7112582-B2 | Bicyclic 6-alkylidene-penems as β-lactamase inhibitors | WYETH (US) | 2006-09-26 | — | — | US | disclosed |
| US-20040077622-A1 | Bicyclic 5-alkylidene-penems as beta lactamases inhibitors | WYETH | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270751-A1 | BENZODIAZEPINE DERIVATIVES USEFUL IN TREATING A RESPIRATORY SYNCYTIAL VIRUS INFECTION | CNR1, CNR2, SIGMAR1 | CYP1A2 389/4885PIK3CA 4608/4885JMJD6 3784/4885 |
| US-20040077622-A1 | Bicyclic 5-alkylidene-penems as beta lactamases inhibitors | PGLS, BPGM, B2M | CYP1A2 106/4885PIK3CA 990/4885JMJD6 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.